Study on how essential thrombocythemia evolves into polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with essential thrombocythemia (ET).
- Your ET has a specific change in the JAK2 gene called JAK2V617F.
- By December 31, 2020, your ET had turned into polycythemia vera (PV).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This Phase 3 study compares ruxolitinib against hydroxycarbamide or interferon as the first treatment for people with high-risk polycythemia vera. It aims to see which option works better to reduce disease-related problems and complications.
This study asks doctors how they diagnose and treat polycythaemia vera (PV), a blood condition where the body makes too many red blood cells. Your answers will help improve care for future patients.
This study follows people with certain chronic blood cancers to understand how the diseases progress and how treatments affect outcomes over time. It may help improve care for future patients.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.